导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 3.81% | 1445/4773 |
| 近一周 | -0.89% | 1946/5467 |
| 近一月 | -4.62% | 1843/5421 |
| 近一季 | -8.97% | 2875/5238 |
| 近半年 | -1.66% | 2037/4931 |
| 近一年 | 5.68% | 1491/4400 |
| 近两年 | 63.29% | 1148/2954 |
| 近三年 | 34.88% | 903/2253 |
| 成立以来 | 46.16% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
1.33% 1310/4961 |
15.59% 1655/5312 |
- - |
- - |
| 2025 | 28.99% 1434/4813 |
2.17% 1449/3635 |
3.10% 1164/4076 |
22.02% 1715/4524 |
0.35% 2046/4813 |
| 2024 | 5.65% 1821/3463 |
-1.12% 1182/2808 |
-1.57% 1077/3014 |
8.99% 2717/3129 |
-0.40% 1410/3463 |
| 2023 | -9.43% 1162/2656 |
5.59% 769/2280 |
-4.46% 1180/2385 |
-5.82% 1382/2515 |
-4.67% 1135/2655 |
| 2022 | -16.87% 526/2207 |
-11.46% 516/1919 |
3.72% 1103/2016 |
-10.71% 441/2113 |
1.38% 1286/2208 |
| 2021 | 21.18% 166/1822 |
-0.17% 338/1255 |
11.06% 403/1330 |
7.18% 194/1466 |
1.99% 730/1822 |
| 2020 | 26.58% 601/1250 |
-6.17% 463/1028 |
20.98% 253/1067 |
10.05% 592/1164 |
1.33% 1038/1184 |
| 2019 | 26.96% 557/1092 |
30.90% 223/739 |
-8.26% 587/788 |
-0.12% 578/850 |
5.85% 669/918 |
| 2018 | - - |
- - |
-12.88% 415/631 |
-9.47% 516/660 |
-12.48% 450/682 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 建信中证500指数增强C VS. 长安沪深300非周期A(740101) |